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Our laboratory has identified reductions in the claudin-5 protein in investigations 
of both a dystrophic cardiomyopathic mouse model and human cardiomyopathy. 
Therefore, it is crucial to study the effects of isolated claudin-5 reductions in a claudin-5 
knockdown (CKD) mouse model to determine whether loss of claudin-5 is sufficient to 
cause cardiomyopathy. Tamoxifen chow administration proved an effective method to 
knockdown claudin-5 expression in the myocardium while avoiding toxicity issues 
apparent with tamoxifen injections. Subsequent serial echocardiograms revealed that 
the experimental CKD mice exhibited initial physiological signs of a cardiomyopathic 
phenotype at 29 weeks of age. Immunofluorescence staining of these experimental 
mice also indicated a slight reduction and irregular staining patterns in the levels of 
claudin-5 and other cardiomyocyte membrane-extracellular matrix proteins. However, 
hematoxylin and eosin staining showed no signs of dilation or damage to the 
myocardium, indicating the lack of a cardiomyopathic phenotype at this timepoint. 
Furthermore, a dobutamine stress test did not induce a cardiomyopathic phenotype in 
experimental mice. This indicated the need to perform longitudinal echocardiograms 
with and without stress in future experiments to determine if these experimental mice 
develop cardiomyopathy as a result of claudin-5 reductions.  
Our laboratory also seeks to determine if claudin-5 ectopic expression is capable 
of maintaining the structural integrity of skeletal muscles in a dystrophin-deficient mouse 
model. Immunofluorescence staining of claudin-5 confirmed that dystrophin-deficient 
skeletal muscle inoculated with a rAAV6-claudin-5 vector containing 5×1011 viral 
genomes exhibited over 70% claudin-5-expressing fibers, and that only 22% of claudin-
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5 expressing skeletal muscle fibers contained central nuclei, an indicator of damage, 
compared to 48% in untreated dystrophic control muscles. Because there is ongoing 
damage in the dystrophin-deficient mouse model, the muscle fibers observed with 
cumulative degeneration and regeneration cycles may have been damaged prior to 
claudin-5 ectopic expression. Though this experiment is most clinically relevant to DMD 
patients that have ongoing damage to their striated muscles, further studies will be able 
to delineate the timing of a claudin-5-based therapeutic treatment in order to prevent 
damage prior to onset, rather than halting damage after onset. This data and its future 
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Duchenne muscular dystrophy (DMD) is a neuromuscular disorder characterized by 
progressive degeneration of striated muscles. This disease is a X-linked recessive form of 
muscular dystrophy, affecting approximately 1 in 5,000 males and resulting in premature death 
around 25 years of age.8 DMD is caused by a mutation in the gene coding for the protein 
dystrophin,7 a cytosolic protein that links actin filaments to the extracellular matrix in striated 
muscle.2,7,10 In the absence of this protein, DMD patients experience decreased structural 
integrity of muscle tissue and impaired contractile function.6,12 Eventually, the muscle tissue 
begins to deteriorate and is replaced by adipose and connective tissue as a result of fibrosis.13 
This process leads to a weakening of the skeletal muscles, causing immobility and respiratory 
diseases because of the rapid degeneration of the limb muscles and diaphragm, respectively.2,3 
More importantly, 95% of DMD patients develop dilated cardiomyopathy, and heart failure is the 
cause of death in at least 25% of patients.3 Though there is currently no cure for DMD, 
treatment is generally aimed at controlling the onset of symptoms to maximize the quality of life, 
which includes glucocorticoids, mineralocorticoid receptor antagonists, and ACE inhibitors, in 
addition to other therapies in clinical trials involving exon skipping and gene therapy. 
Dilated Cardiomyopathy 
Dilated cardiomyopathy (DCM) is a common cause of heart failure in both DMD patients 
and the general population.3 DCM is a cardiac disease that is primarily characterized by force 
reductions in the left ventricle. The reductions in force cause the cardiomyocytes of the left 
ventricle to stretch and become thinner, resulting in dilation of the myocardium. Dilation causes 
the myocardium to weaken and eventually remodel, which manifests as cardiac chamber wall 
thinning and changes in chamber geometry to a more spherical, less elongated shape. The 
remodeling process causes a continuous decline in ejection fraction, the blood volume pumped 
out of the left ventricle with each heartbeat, and this prevents the heart from adequately 
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supplying the body’s tissues and organs with enough blood. Over time, this condition can cause 
heart failure. Whereas the effects of DCM have been identified, the mechanism of DCM remains 
unknown.  
Claudin-5 
Our laboratory has recently identified claudin-5 as a protein that becomes reduced early 
in the progression of DCM.3 Claudin-5 is a transmembrane protein found as a component of 
tight junctions. In cardiac muscle, claudin-5 is localized at membrane-matrix junctions, linking 
the lateral cardiomyocyte membrane to the extracellular matrix. Loss of cardiac membrane-
matrix interactions can contribute to the remodeling that manifests in DCM and heart failure.10 
Because claudin-5 is localized to the membrane-matrix junction, a decrease in claudin-5 could 
result in weak membrane-matrix binding, ultimately leading to the development of DCM.10 
Despite the reduction in claudin-5, the levels of other structural proteins remain unaltered,9 
suggesting that alterations in claudin-5 levels may represent a critical step in DCM progression.  
Role of Claudin-5 in Dilated Cardiomyopathy 
Several studies performed in our laboratory have suggested that reductions in claudin-5 
contribute to cardiac dysfunction during the early stages of the progression of DCM. Reduced 
claudin-5 levels were first correlated with DCM using a dystrophic cardiomyopathic mouse 
model. Compared to mice with a mild cardiomyopathy, reduced claudin-5 levels were observed 
in cardiac tissue from dystrophic cardiomyopathic mice via mRNA microarray analysis.11 To 
further characterize the relationship between claudin-5 and DCM, my laboratory conducted a 
claudin-5 rescue experiment in this dystrophic cardiomyopathic mouse model. My laboratory 
showed that sustained claudin-5 levels in these mice prevented physiological and histological 
signs of cardiac dysfunction.3 To investigate the relevance of reduced claudin-5 levels to human 
DCM, claudin-5 levels were compared in heart tissue from normal patients and patients with 
heart failure.9 Claudin-5 levels were reduced in 60% of patients with heart failure, and this was 
independent of whether patients had muscular dystrophy-related DCM.7 These studies suggest 
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that reduced claudin-5 levels may be involved in cardiomyopathy regardless of etiology.9 
Though reduced claudin-5 levels have been correlated with DCM, these studies aim to identify a 
direct link between loss of claudin-5 and development of DCM.  
Significance 
Heart disease is the leading cause of death in the United States. It often remains 
undiagnosed and end-stage heart disease is incurable. The study of DCM is significant because 
it is a common cause of heart failure that affects a large population, resulting in 50,000 
hospitalizations a year and over 10,000 deaths in the United States alone.4,14 Despite its 
prevalence, the mechanisms leading to DCM are unknown; therefore, it is crucial to discover 
novel pathways involved in the development of DCM. The proposed studies could identify loss 
of claudin-5 as a necessary step in DCM and determine how claudin-5 reductions are involved 
in the larger patient population. The information from these experiments could also be used to 
establish the potential therapeutic value of claudin-5. Restoring claudin-5 levels could be used 
to prevent further cardiomyocyte damage and potentially improve the condition of the heart in 
patients suffering from DCM.7 
Research Aims 
The purpose of the first aim was to determine if a reduction in claudin-5 is sufficient to 
cause cardiac dysfunction characteristic of DCM. Claudin-5 reductions are present in cardiac 
tissue in investigations of both a dystrophic cardiomyopathic mouse model and human 
cardiomyopathy patients, suggesting that claudin-5 may be the cause of cardiac dysfunction 
during the development of DCM. This aim utiliized claudin-5 knockdown (CKD) mice to 
determine whether a direct link exists between reduced cardiac claudin-5 levels and cardiac 
dysfunction associated with DCM. We hypothesized that reductions in claudin-5 in 
cardiomyocytes would compromise cardiac muscle function and morphology in the CKD mouse 
model. To address this aim, the effects of claudin-5 reductions in relation to cardiomyopathy in a 
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CKD mouse model were investigated in order to define the physiological, cellular, and molecular 
mechanisms of DCM resulting from loss of claudin-5.  
The purpose of the second aim was to determine if upregulating claudin-5 levels is also 
capable of maintaining the structural integrity of skeletal muscle in a dystrophin-deficient mouse 
model. Our laboratory previously demonstrated that sustaining claudin-5 expression via delivery 
from a gene therapy vector prevented cardiac dysfunction and histopathology in utrophin-
deficient dystrophic mice, supporting that claudin-5 may represent a therapy for patients 
suffering from DMD. We hypothesized that claudin-5 ectopic expression would help compensate 
for dystrophin-deficiency in skeletal muscle, by replacing missing muscle membrane-
extracellular matrix linkages. To address this aim, claudin-5 was delivered to dystrophin-
deficient skeletal muscle via rAAV6-claudin-5 vector to transduce a majority of muscle fibers in 
the tibialis anterior (TA) muscle located in the anterior compartment of the lower hind limb, 
which is in ideal position for needle injections.  
  
 12 
VI. Methods  
 
Methods for Aim 1: To determine whether claudin-5 reduction in cardiomyocytes is 




My laboratory developed a claudin-5 knockdown (CKD) mouse model using the 
MerCreMer-Lox system to specifically and inducibly reduce claudin-5 in a cardiac tissue-specific 
knockdown. This mouse model was designed to excise the single claudin-5 exon from 
chromosome 16 in cardiomyocytes.12 These mice contain two loxP sites that flank the single 
claudin-5 exon (“floxed”). This system utilizes a transgene that expresses a cre recombinase 
protein. This enzyme binds to the loxP sites and causes homologous recombination through 
inversion, deletion, or translocation to excise the claudin-5 exon. After the creation of the floxed 
construct, it was transfected into 129SV mouse embryonic stem cells. A neomycin antibiotic 
resistance cassette (Neo) was also contained in the floxed construct, and neomycin-resistant 
cells that contained the floxed construct were later implanted into the blastocytes of pregnant 
mice. The neomycin antibiotic resistance cassette was flanked by two frt sites to allow for 
removal of the neomycin cassette via the flp recombinase protein. Therefore, mice that 
contained the floxed claudin-5 construct with Neo flanked by frt sites were bred with mice 
expressing flp recombinase to remove the Neo cassette. To create the CKD experimental mice, 
mice that expressed the floxed construct without the Neo cassette and flp transgene were bred 
with mice that expressed cre recombinase. The cre recombinase was driven by the 
cardiomyocyte-specific promoter alpha myosin heavy chain 6 and was flanked by two mutated 
estrogen responsive elements (MerCreMer). These Mer elements were created to respond only 
to non-endogenous estrogen agonists, such as tamoxifen, and therefore, prevent cre 
recombinase from entering the nucleus of the cell in the presence of endogenous estrogen. 
When tamoxifen is present, cre recombinase enters the nuclei in cardiomyocytes and causes 
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recombination between the loxP sites in chromosome 16, excising the claudin-5 exon and 
preventing subsequent protein expression in the myocardium only.10 The mice that expressed 
cre recombinase and flp recombinase were purchased from The Jackson laboratory.  
 
Figure 1. Schematic representation of the claudin-5 floxed allele that would be found in 
experimental mice after the homologous recombination event. The single claudin-5 
exon is flanked by two loxP sites at the 5’ and 3’ ends. The neomycin antibiotic 
resistance cassette is flanked by two frt sites at the 5’ and 3’ ends. Mice possessing the 
floxed claudin-5 construct with Neo were bred with mice expressing flp recombinase to 
remove the Neo cassette, represented by the black “X.” Mice without the Neo cassette 
and flp transgene were bred with that expressed cre recombinase. These experimental 
mice were then treated with tamoxifen to generate a cardiac-specific knockdown using 
the MerCreMer-Lox system. 
 
 
The creation of a knockdown strain was necessary because a claudin-5 knockout in 
floxed/floxed mice without the neomycin cassette was found to be preneonatal lethal. The 
claudin-5 exon is 2.1 kilobases upstream from the first exon of CDC45, a gene required for 
postimplantation mouse development, and deletion of neomycin from the 3’ intron could affect 
the CDC45 gene and result in neonatal death of floxed/floxed mice.  
Experimental heterozygous claudin-5 flox+/- mice that contain cre (Cldn5 flox+/-; cre+/-, 
referred to as het cre+) often exhibited reduced claudin-5 levels in the myocardium at 
membrane-matrix junctions after tamoxifen administration compared to wild-type mice that do 
not contain cre (Cldn5 flox-/-; cre-/-, or wt cre-).7 Similar reductions in claudin-5 are observed in 
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other animal models and human patients with cardiomyopathy, suggesting that the CKD mouse 
model may represent a clinically-relevant animal model of cardiomyopathy. Het cre- 
(heterozygous Cldn5 flox+/-; cre-/-) and wt cre + (Cldn5 flox-/-; cre+/-) mice were also bred for 
use as experimental controls for the floxed claudin-5 allele and for the presence of cre. 
Breeding 
All animals were mated and kept in accordance with a protocol approved by the 
Institutional Animal Care and Use Committee at The Ohio State University. Het cre+ mice were 
bred with wt cre- mice. This breeding scheme produced litters with half heterozygous mice and 
half wild-type mice. It also produced litters with half cre+ and half cre- mice. This provided a 
variety of controls for the experimental het cre+ mice. 
DNA Extraction 
 
At three weeks of age, one centimeter of tail was snipped from the mice and suspended 
in 600 μl of TNES buffer (0.5 M Tris-HCl pH 7.5, 5 M NaCl, 0.5 M EDTA, 10% sodium dodecyl 
sulfate) and 17.5 μl of 20 mg/ml proteinase K to incubate at 55 C overnight. An additional 50 μl 
of proteinase K was added to tails that had not fully digested in the overnight incubation. Upon 
complete digestion of the tail, 167 μl of 5 M NaCl was added to each tube and the tubes were 
shaken for 15 seconds. The tubes were then centrifuged for 10 minutes at 4 C at 14,000 rpm. 
The supernatant was poured into a new tube and 800 μl of 100% cold ethanol was added to 
each tube and mixed. The DNA was spooled onto the sealed end of a Pasteur pipette and 
rinsed in 70% ethanol. The DNA was then resuspended in 300 μl 1X TE buffer (10 mM Tris-HCl 
pH 8.0, 1 mM EDTA) and incubated for 10 minutes at 65 C. The DNA was stored in this buffer 
at 4 C.  
Polymerase Chain Reaction 
 
Polymerase chain reaction (PCR) was used to identify genotypes for appropriate 
breeding mice and experimental analysis. At three weeks of age, one centimeter of tail was 
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snipped from the mice and digested to extract DNA for genotyping according to the standard 
salt-out extraction protocol as previously described. PCR reactions were conducted using the 
CreER primers (Forward: CCGGTCGATGCAACGAGTGAT, Reverse: 
ACCAGAGTCATCCTTAGCGCC, 59 C annealing temperature), 5’LoxP primers (Forward: 
ACCAGAGTCATCCTTAGCGCC, Reverse: CGAAGTTATTAGGTCCCTCGACC, 62 C 
annealing temperature), and wildtype primers (Forward: 
GGAGAAGAACCTACTGAACCAAAGG, Reverse: TCACCCAAGTTGCCATTCCC, 59 C 
annealing temperature). These primers were designed to detect the presence of the cre 
transgene, the floxed construct, and the wildtype product, respectively. The PCR reaction 
contained 7.5 μl 2X Syzygy Taq master mix, 0.3 μl forward primer, 0.3 μl reverse primer, 5.9 μl 
distilled water, and 1μl of DNA. ΦX HaeIII was used as the molecular weight marker. PCR 
products were separated by gel electrophoresis on 2% agarose gels and visualized via 
ultraviolet light. The presence of a PCR product at 798 base pairs (bp) using the CreER primers 
indicated the presence of the cre recombinase gene. The presence of the 5’loxP product was 
determined by the presence of a ~600 bp product when the reaction was run with 5’loxP 
primers. This product indicated that at least one allele contained the 5’loxP construct. A wildtype 
primer reaction was used to determine the presence of the wildtype allele, with the wildtype 
product present at ~550 bp. Heterozygous mice show two products, one for the wildtype product 
and a longer one for the 5’loxP product. 
PCR was also utilized to determine if tamoxifen chow-treated mice excised the claudin-5 
exon. Hearts were dissected from experimental het cre+ mice and a small portion of the heart 
was digested to isolate DNA for PCR analysis. The standard salt-out extraction protocol outlined 
above was followed with primers designed to detect the presence of the floxed construct. PCR 
products that appeared at 2027 bp denoted the presence of the large floxed construct in the 
myocardium of the tamoxifen-treated mice, indicating incomplete excision of the claudin-5 exon. 
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PCR products that appeared at 564 bp revealed deletion of the floxed construct in the 
myocardium of the tamoxifen-treated mice, indicating complete excision of the claudin-5 exon. 
Tamoxifen Injection 
 
At 4 weeks of age, het cre+ male and female mice and all genotypes of controls 
(wt cre+, wt cre-, het cre-) (Group A, n=75) were injected with tamoxifen (Sigma) 
dissolved in corn oil at 20 mg/ml. The mice were administered 200 mg/kg per day of 
tamoxifen per body weight. Tamoxifen was administered via intraperitoneal injection for 
5 consecutive days.  
Tamoxifen Chow 
 
 Due to toxicity issues, tamoxifen administration switched from injections to chow. 
Tamoxifen chow contained 400 mg/g of tamoxifen citrate/kg Teklad Global 16% Protein Rodent 
Diet at an estimated dose of approximately 40 mg/kg per day for two consecutive weeks, which 
was administered beginning at four weeks of age to het cre+ male and female mice and all 
genotypes of controls (wt cre+, wt cre-, het cre-) (Group B-E, n=93).  
Experimental Design  
To induce excision of the claudin-5 exon via the most efficient administration of 
tamoxifen, Group B was treated with tamoxifen chow for 2 weeks starting at 4 weeks of age and 
compared to the Group A mice that were treated with tamoxifen injections for 5 consecutive 
days beginning at 4 weeks of age. This experimental design was intended to demonstrate 
whether tamoxifen chow excised the claudin-5 exon and eliminated toxicity issues apparent with 
tamoxifen injections in the CKD mouse model.  
After confirming successful excision of the claudin-5 exon via tamoxifen chow treatment, 
all male and female mice from Groups C-E were treated with tamoxifen chow for 2 weeks 
starting at 4 weeks of age to induce deletion of the claudin-5 exon. Primary comparisons were 
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performed in het cre+ and wt cre- mice. However, tamoxifen-treated het cre- and wt cre+ were 
also included to control for the floxed claudin-5 allele and for the presence of cre.  
 
 
Table 1. CKD mice groups and treatments. 
Group Mice used Treatment Purpose Age at death 
(weeks) 
A (n=75) Experimental:  
het cre+ 
Control: wt cre-, wt 







B (n=10) Experimental:  
het cre+ 
Control: wt cre-, wt 
cre+, het cre- 







C (n=37) Experimental:  
het cre+ 
Control: wt cre-, wt 
cre+, het cre- 




D (n=26) Experimental:  
het cre+ 
Control: wt cre-, wt 
cre+, het cre- 






E (n=15) Experimental:  
het cre+ 
Control: wt cre-, wt 
cre+, het cre- 
Tamoxifen chow To conduct 
dobutamine 










Dr. Mohammad Elnakish from Dr. Paul Janssen’s laboratory performed serial 
echocardiograms on Group C at 14 weeks of age, Group D at 20, 25, and 29 weeks of age, and 
Group E at 25 weeks of age to determine ejection fractions and calculate left ventricle 




Jori Chambers, Lauren Chen, and Jenny Lee from the Rafael-Fortney Laboratory at The 
Ohio State University College of Medicine conducted a dobutamine stress test on Group E mice 
at 20 weeks of age to investigate the effects of reduced claudin-5 on whole heart function 
following β-adrenergic stimulation. Each mouse was intraperitoneally injected with dobutamine 
(20 μm/gbody weight) diluted in 0.9% saline twice daily for seven days. On the seventh day, cardiac 
function was assessed via echocardiography. Mice were then monitored continuously for the 
first hour and at twenty-minute intervals for nine hours. No acute cardiac death was observed in 
all genotypes of mice after 48 hours following the seventh dobutamine injection. Mice were 
dissected and cardiac tissue was harvested as detailed below. Damage to the myocardium was 
visualized by immunohistochemical staining under brightfield and fluorescent microscopy. 
Dissections 
 
Group C mice were dissected at 14 weeks of age and Group D mice were dissected at 
29 weeks of age to assess the severity of cardiac damage due to loss of claudin-5. A blood 
sample was obtained and centrifuged to collect serum. The heart was removed and cut 
transversely into two sections. The inferior half was embedded in optimal cutting temperature 
(OCT) medium and frozen on liquid nitrogen-cooled isopentane for histological sectioning while 
the superior half was frozen in liquid nitrogen for subsequent protein and DNA isolation. The 
quadriceps muscle was removed and cut transversely, and one section was frozen in liquid 
nitrogen and the other was frozen in OCT for sectioning. The lungs, liver, and kidney were 
removed and frozen in liquid nitrogen. Tissue samples embedded in OCT were cut into 8 μm 




Heart sample slides were warmed to room temperature and the sections were encircled 
with a hydrophic pen. The slides were equilibrated in a potassium phosphate buffered solution 
(KPBS: K2HPO4, KH2PO4, NaCl) for five minutes. They were blocked with KPBS +1% gelatin for 
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fifteen minutes and rinsed with KPBS for five minutes. The slides were incubated in 100 µL of a 
primary antibody (see Table 2) for two hours at room temperature in a humid chamber. The 
antibody was diluted to its optimal dilution with KPBSG (KPBS + 0.2% gelatin) and 1% normal 
goat serum (NGS). The slides were rinsed for five minutes three separate times in KPBSG. The 
slides were then incubated in 100 µL of a secondary antibody for one hour at room temperate in 
a wet chamber in the absence of light. The secondary antibody was diluted to its optimal dilution 
with KPBSG and NGS. The slides were washed with KPBSG for five minutes three separate 
times. Each slide was mounted with 35 µL of a solution of vectashield and DAPI, which stains 
nuclei, (at 2 µL/ml) and coverslipped. The slides were stored in a -20°C frost-free freezer. These 
sections were visualized and photographed at fixed exposure times on a Nikon Eclipse 800 
Microscope with an epifluorescent mercury lamp using a SPOT camera and software. Images of 
each antibody stain was taken at the same exposure for each experiment to ensure consistency 
between samples. 
Table 2. Primary* and secondary** antibodies used for immunofluorescent staining.  
Antibody 
(Species) 
Company Dilution Other Specifications 
Claudin-5* 
(Rabbit) 
Acris 1:750 None 
Ephrin B1* 
(Goat) 
R&D Systems 1:25 Fetal Bovine serum 
used instead of NGS 
Collagen* 
(Rabbit) 
Abcam 1:100 None 
Fibronectin* 
(Rabbit) 
Abcam 1:40 None 
Immunoglobulin G** 
(Mouse) 
Invitrogen 1:100 None 
 
 
Hematoxylin and Eosin Staining 
Heart tissue samples were also stained with hematoxylin, which stains nuclei, and eosin, 
which stains cytosol and extracellular material, to visualize the overall morphology of the 
myocardium. The slides were stained using a standard protocol with appropriate ethanol 
dehydration steps. The slides were fixed with 100% ethanol for 30 seconds at room temperature 
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and subsequently washed in tap water. The slides were then stained with hematoxylin for 30 
seconds and washed in tap water. The slides were stained with eosin for 20 seconds and 
washed in tap water. They were then dehydrated in 100% ethanol, 90% ethanol, and 70% 
ethanol and washed with histochoice clearing agent. The slides were mounted with cytoseal and 
coverslipped. The slides were then visualized on a light microscope and images were taken 
using Advanced Spotware technology. Individual pictures taken at 4X magnification were 
composited using Adobe PhotoShop. 
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Methods for Aim 2: To determine whether claudin-5 expression helps protect skeletal 
muscle from the degenerative effects of dystrophin-deficiency. 
 
Animal Design 
The mdx (Dmdmdx; utrn+/+) model is a murine model of DMD, which arises from a 
spontaneous mutation in the dystrophin gene. Mdx mice, like DMD patients, lack dystrophin and 
have previously been identified to exhibit mild skeletal muscle fibrosis and mild cardiomyopathy. 
Therefore, this mouse model is appropriate for testing therapeutic intervention at the early 
stages of disease.  
rAAV-claudin-5 vector 
 
A recombinant AAV6-claudin-5 vector carrying a mouse claudin-5 cDNA expressed from 
a minimal cytomegalovirus promoter (rAAV6-claudin-5; 1 x 1011 viral genomes) was designed to 
deliver claudin-5 to skeletal muscles. This rAAV6 vector has previously been shown to confer 




 Prior to the muscle injection, each mouse was anesthetized via the nose cone method. 
During the initial induction stage, oxygen flow was 2 liters/minute with 5% isofluorane. Once 
reflexes became absent and mouse respirations became slow, shallow breaths, oxygen flow 
was reduced to 0.8 liters/minute with 2% isofluorane to maintain loss of consciousness. One 
drop of Nair was applied to the right leg and removed with a non-woven sponge. It was washed 
with PBS and 100% ethanol to prevent skin irritation. A syringe (3/10 cc U-100 Insulin syringe) 
was loaded with 30 µl of sterile PBS and the needle (30G x 3/8 inch needle) was bent to 90° 
angle. The needle was then injected into the TA muscle belly near the junction of TA and 
extensor digitorum longus (EDL) muscles. These steps were repeated with injection of the virus 
into the left leg. The isoflourane and oxygen were removed following injections, and the mouse 
was monitored for movement and normal, rapid breaths.  
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Experimental Design 
Four-week-old weaned male and female mdx mice (Group 1; n=5), which exhibit 
histological and physiological signs of skeletal muscle pathology, were injected with a rAAV6-
claudin-5 vector at 1 x 1011 viral genomes (vg) in phosphate-buffered saline (PBS) via 
intramuscular injection into the TA muscle. To control for the mechanics of injecting the mice 
and to compare the normal protein levels of claudin-5 for experiments, the contralateral TA 
muscle was injected with an equivalent volume (30 µl) of PBS.  
Titration experiments were performed with the goal of achieving complete transduction 
of claudin-5 in skeletal muscle fibers.  rAAV6-claudin-5 was tested at 5 x 1011 and 1 x 1012 vg in 
mdx mice (Group 2; n=2).  
Upon confirmation that rAAV6-claudin-5 transduced more than 50% of skeletal muscle 
fibers, the vector was administered at 5 x 1011 vg to additional mdx mice (Group 3; n=5).  
Table 3. Mdx mice groups and treatments. 
Group Mice used Treatment 
(via TA muscle 
injections) 
Purpose Age at death 
(weeks) 
1 5 rAAV6-claudin-5 
vector at 1 x 1011 
vg and PBS 








2 2 rAAV6-claudin-5 
vector at 5 x 1011 






skeletal muscle  
8 
3 5 rAAV6-claudin-5 
vector at 5 x 1011 
vg and PBS 
To achieve the 
purposes of 









Mdx mice in Groups 1, 2, and 3 were dissected at 8 weeks of age to assess if claudin-5 
ectopic expression helped compensate for dystrophin-deficiency in skeletal muscle. The TA, 
EDL, and quadriceps muscles were removed and cut transversely into two sections. The 
superior half was embedded in OCT and frozen on liquid nitrogen-cooled isopentane for 
histological sectioning while the inferior half was frozen in liquid nitrogen for protein isolation. 
Tissue samples embedded in OCT were cut into 8 µm sections using a cryostat, mounted on 
slides, and stored at -80°C.   
Immunofluorescence 
 
As described for Aim 1.  
 
Hematoxylin and Eosin Staining 
As described for Aim 1.  
 
Central Nuclei Quantification 
 Mdx mice TA muscles treated with rAAV6-claudin-5 in Groups 1, 2, and 3 were 
immunofluorescently stained with a polyclonal claudin-5 antibody and pictures of merged 
claudin-5 and DAPI stains were taken at the same exposure time and magnification. Because 
central nuclei in skeletal muscle fibers are an indicator of previous damage and subsequent 
regeneration of the muscle fiber, the number of central nucleated claudin-5-expressing muscle 








Results for Aim 1: To determine whether claudin-5 reduction in cardiomyocytes is 
sufficient to cause cardiomyopathy. 
 
A. Tamoxifen chow treatment was an effective method to excise the construct 
containing the single claudin-5 exon. 
 
Previous results showed that tamoxifen administration via injections to excise the construct 
containing the single claudin-5 exon in the CKD mouse model exhibited cre-dependent toxicity, 
which resulted in accelerated reduction of whole heart function in het cre+ and wt cre+ mice. As 
a result, tamoxifen was alternatively administered in a mouse chow at a lower dose and longer 
period of administration to alleviate the high toxic dose and invasiveness of tamoxifen injections. 
DNA from hearts of tamoxifen-injected (Group A) and tamoxifen chow-treated (Group B) mice at 
14 weeks of age was isolated and amplified in PCR experiments to compare if the construct had 
been excised (Figure 2). The presence of the upper band at 2027 base pairs (bp), produced 
from a PCR reaction using primers surrounding the claudin-5 exon and loxP sites, indicated 
incomplete excision of the exon, whereas the presence of the lower band at 564 bp implied 
complete excision of the construct in het cre+ mice. Analysis of this data showed successful 
excision of the construct in both tamoxifen-injected and tamoxifen chow-treated het cre+ mice, 

















        Tamoxifen Injected        Tamoxifen Chow 
 
 
Figure 2. Example of PCR DNA product bands from genotyping experiments. *Bands present at 
564 bp indicated complete excision of the construct containing the claudin-5 exon, while bands 
present at 2027 bp indicated incomplete excision of the construct. PCR analysis indicated that 
mice treated with tamoxifen chow (two-week treatment at ~40 mg/kg per day) excised the 
construct, with similar success compared to mice injected with tamoxifen (five day treatment at 
200 mg/kg per day).  
 
B. Experimental het cre+ mice exhibited no observable cardiomyopathic 
phenotype at 14 weeks of age. 
 
Because tamoxifen chow treatment successfully excised the construct containing the 
claudin-5 exon, mice of all four genotypes of the CKD model were treated with tamoxifen chow 
to knockdown the claudin-5 gene expression and determine the timepoint at which mice may 
develop DCM due to loss of claudin-5. Previous data showed that at 14 weeks of age, het cre+ 
mice did not exhibit an average ejection fraction within the range indicative of a cardiomyopathic 
phenotype (unpublished). These mice were dissected at 14 weeks of age, and their myocardium 
was harvested and studied using immunohistochemical stains. Immunofluorescence staining 
analysis (Figure 3) showed no significant changes in the levels of claudin-5 or ephrin B1, a 
membrane-matrix protein that interacts with claudin-5 in the myocardium. No significant 
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changes in the levels of collagen, an extracellular matrix protein, indicated the absence of 
collagen scarring, or gross increases in the amount of interstitial collagen, therefore 
demonstrating the presence of maintained structure and integrity of the myocardium. 
Hematoxylin and eosin staining showed no major dilation of the left ventricle, necrosis of 
myocytes, or increased fibrosis that might indicate a cardiomyopathic phenotype. Thus, at 14 
weeks of age, het cre + mice treated with tamoxifen chow showed no major reduction of 





Figure 3. Immunohistochemical staining of heart sections of experimental mice and controls at 
14 weks of age. Immunohistochemical staining of het cre+ mice at 14 weeks of age for these 
four markers (left axis) showed no major reduction of claudin-5 levels or changes in cell 
pathology in the myocardium in comparison of each genotype (top axis) to indicate the presence 
of a cardiomyopathic phenotype. Top row: Hematoxylin and eosin staining appeared consistent 
between the experimental het cre+ mice (n=12) and control mice, wt cre- (n=7), wt cre+ (n=13), 
and het cre- (n=10) and did not exhibit signs of dilation, necrosis of myocytes, or increased 
fibrosis indicative of a cardiomyopathic phenotype. Second row: Claudin-5 staining is not 
reduced when comparing immunostaining of het cre+ experimental mice and control mice. Third 
row: Staining of experimental het cre+ for ephrin B1, a membrane-matrix protein that interacts 
with claudin-5 in the myocardium, was not reduced compared to control mice. Bottom row: 
Collagen I staining showed no changes in the levels of collagen, an extracellular matrix protein, 
demonstrating the absence of collagen scarring and maintained cardiomyoctye membrane 




C. Serial echocardiograms of het cre+ mice revealed initial physiological signs of 
a cardiomyopathic phenotype. 
 
 Because no cardiomyopathic phenotype was oberved at 14 weeks of age, another group 
of mice (Group D; n=26) was treated with tamoxifen chow and underwent serial 
echocardiograms at 20 weeks of age (Figure 4A), 25 weeks of age (Figure 4B), and 29 weeks 
of age (Figure 4C). At 20 weeks of age, het cre + mice had reduced ejection fractions of 57.3%, 
56.4% at 25 weeks of age, and 54% at 29 weeks of age, which remained consistently slighty 
lower than the other genotypes (Figures 4A-C). Ejection fraction data was not significantly 
different based on treatment groups (P= 0.340), length of time (P= 0.980), or interactions 
between treatment groups and length of time (P= 0.504) according to a 2-way ANOVA repeated 
measures. Because severe cardiac dysfunction has an average ejection fraction of 55% or 






Figures 4A-C. Longitudinal echocardiogram average ejection fraction data. Experimental het 
cre+ mice (n=8) exhibit, on average (indicated by line), lower ejection fractions than each control 
group, wt cre- (n=8), wt cre+ (n=3), het cre- (n=7), at 20 weeks of age (4A), 25 weeks of age 
(4B), and 29 weeks of age (4C). Though a two-way ANOVA repeated measures test indicated 
that ejection fraction data was not significantly different based on treatment groups, length of 
time, or interactions between treatment groups and length of time, a trend of reduced ejection 
fractions over time in experimental het cre+ mice hearts was observed. Furthermore, 
experimental het cre+ mice at 29 weeks of age exhibited an average ejection fraction of 54%, 
which is in the clinical range of severe cardiac dysfunction, and indicated that these mice 




Group D mice were dissected at 29 weeks of age to determine if a reduction of claudin-5 
was sufficient to cause histopathological signs of a cardiomyopathic phenotype that preceded 
physiological symptoms of DCM. Claudin-5 immunofluorescence staining of 29 week old CKD 
mouse hearts showed a slight reduction of claudin-5 in the cardiomyocyte membranes of het 
cre+ mice in a mosaic pattern (Figure 5), likely due to the stochastic nature of cre excision of the 
claudin-5 allele in the myocardium. Ephrin B1 immunofluorescence staining showed that ephrin 
B1 was similarly stained in a mosaic pattern in het cre+ mice, however, without a major 
observable loss of ephrin B1 expression. Fibronectin, an extracellular matrix protein similar to 
collagen I, revealed several irregular areas of increased fibronectin staining in het cre+. This 
indicated the presence of extracellular matrix proliferation and scarring in the myocardium, 
possibly resulting from claudin-5 reduction.  
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Figure 5. Immunofluorescence staining of heart sections of experimental mice and controls at 
29 weeks of age. Top row: Claudin-5 staining is slightly reduced in the membranes of 
cardiomyocytes in a mosaic pattern in experimental het cre+ mice (n=8) compared to wt cre- 
(n=8), wt cre+ (n=3), and het cre- (n=7). Middle row: Ephrin B1 staining showed reduced ephrin 
B1 expression in experimental het cre+ mice also in a mosaic pattern similar to claudin-5 
staining (top row), compared to control mice. Bottom row: Fibronectin staining, an extracellular 
matrix protein, exhibited irregular patterns of staining in experimental het cre+ mice, which 
indicated the presence of extracellular proliferation and scarring, possibly due to loss of claudin-
5. (Bar equals 100µm) 
  
 Despite these changes in protein expression and reduction in ejection fractions in het 
cre+ mice, hematoxylin and eosin staining of 29 week old CKD mouse hearts exhibited no signs 
of dilation or damage to the myocardium (Figure 6). This indicated a lack of a cardiomyopathic 
phenotype at this timepoint in het cre+ mice. However, an additional group of mice are currently 
being studied to gather longitudinal echocardiogram data in order to determine the timepoint at 







Figure 6. Histology of composited heart sections from experimental het cre+ mice and controls. 
Hematoxylin and eosin staining of transverse sections of left ventricles from experimental het 
cre+ mice hearts (n=8) at 29 weeks of age compared with control mice hearts, wt cre- (n=8), wt 
cre+ (n=3), and het cre- (n=7). Experimental het cre+ mice hearts showed no signs of dilation or 





D. Dobutmine stress test did not induce a cardiomyopathic phenotype in het cre+ 
mice.  
 
To test whether the CKD mice exhibit cardiomyopathy under stress, a group of CKD 
mice (Group E; n=15) were given serial injections of the β-adrenergic agonist dobutamine (20 
µg/gbody weight in 0.9% saline twice daily/1 week). Het cre+ mice at 25 weeks of age following 
dobutamine injections exhibited increased heart rates (462.06 beats/minute) compared to wt 
cre- mice (421.29 beats/minute; het cre-: 489.68 beats/minute; wt cre+: 423.83 beats/minute) 
and decreased ejection fractions (58.43%) compared to wt cre- mice (67.99%; wt cre+ 56.24%; 
het cre- 74.34%). These results also showed that 25 week old tamoxifen-treated het cre+ mice 
stressed with dobutamine (Group E) had slightly elevated ejection fractions compared to 
tamoxifen-treated 25 week old het cre+ mice (Group D), indicating that the dobtumine stress 
test did not induce a physiological cardiomyopathic phenotype in het cre+ mice.   
These mice were dissected at 25 weeks of age to investigate the histopathological effect 
of claudin-5 reduction in the myocardium of dobutamine-stressed mice. Claudin-5 
immunofluorescence staining showed a reduction of claudin-5 in the membranes of 
cardiomyocytes in a mosaic pattern compared to other genotypes (Figure 7). IgG 
immunofluorescence staining was used to detect serum IgG accumulation in the myocardium 
indicative of myocytes with membrane damage or regions of fibrosis. This showed several 
fibrotic regions (indicated by bright green) primarily in whole heart composites of het cre+ mice, 
indicating that loss of claudin-5 in dobutamine-stressed CKD mice may have resulted in damage 
to the myocardium (Figure 8, top row). Hematoxylin and eosin staining of het cre+ mice did not 
reveal any signs of dilation or damage to the myocardium (Figure 8, bottom row), indicating the 
lack of a histopathological cardiomyopathic phenotype.  
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Figure 7. Claudin-5 immunofluorescence staining of heart sections of dobutamine-stressed 25 
week-old experimental het cre+ and control mice hearts. Claudin-5 staining was reduced in the 
myocardium of dobutamine-stressed experimental het cre+ mice (n=3) in a mosaic pattern, 
compared to dobutamine-stressed wt cre- (n=4), wt cre+ (n=4), and het cre- (n=3).  
(Bar equals 100µm) 




Figure 8. Top: IgG staining of composited heart sections of dobutamine-stressed experimental 
het cre+ mice and controls. IgG immunostaining of transverse sections of whole heart 
composites shows several regions of damage in experimental het cre+ mice (n=3), compared to 
wt cre- (n=4), wt cre+ (n=4), and het cre- (n=3), indicating that claudin-5 reductions in 
dobutamine-stressed het cre+ mice may have resulted in damage to the myocardium. Note that 
the bright green staining in wt cre- is indicative of vessels. Bottom: Hematoxylin and eosin 
staining of composited heart sections of dobutamine-stressed experimental het cre+ and control 
mice. Immunohistochemical staining did not show any signs of dilation or damage to the 
myocardium consistent with cardiomyopathy. (Bar equals 1mm) 
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Results for Aim 2: To determine whether claudin-5 expression helps protect skeletal 
muscle from the degenerative effects of dystrophin-deficiency. 
 
E. Claudin-5 ectopic expression via rAAV6-claudin-5 (1 x 1011vg) prevented 
damage to the muscle membrane in dystrophin-deficient skeletal muscle. 
 
Four week-old mdx mice (Group 1, n=5) were injected with a rAAV6-claudin-5 vector at 1 
x 1011 vg in PBS and an equivalent volume of PBS, as the control, via intramuscular injections 
into the left and right TA muscles, respectively. These mice were dissected at eight weeks of 
age to ensure that claudin-5 had transduced the maximal amount of skeletal muscle fibers. The 
injected TA muscles were harvested and studied using immunohistochemical stains to 
determine if claudin-5 ectopic expression would help prevent damage to the muscle membrane. 
Claudin-5 (red) immunofluorescence staining of rAAV6-claudin-5-injected TA muscles 
demonstrated that treatment with this vector is able to transduce skeletal muscle fibers and 
upregulate claudin-5 expression levels in the mdx mouse model (Figure 9A), as compared to 
the PBS-injected TA muscle (Figure 9D). Merged images of claudin-5 and DAPI (blue) 
immunofluorescence staining (Figures 9B and 9E) of the injected TA muscles showed that the 
claudin-5 expressing muscle fibers did not exhibit a large number of fibers with central nuclei, 
which is a marker of cumulative degeneration and regeneration cycles that indicate damage to 
the muscle fibers. This data indicates that the upregulation of claudin-5 exhibited protective 
effects in dystrophin-deficient skeletal muscle because it prevented damage to the muscle 
membrane. Hematoxylin and eosin staining on these injected TA muscles showed more regions 
of damage to the skeletal muscle in PBS-injected mdx mice (Figure 9F) compared to rAAV6-
clauudin-5 vector-injected mice (Figure 9C). To serve as an untreated control, the quadriceps 
muscles on rAAV6-claudin-5- and PBS-injected legs were also harvested and stained with 
claudin-5 and DAPI to demonstrate the lack of high-expressing claudin-5 fibers in untreated 
dystrophin-deficient skeletal muscles (data not shown). The lack of high-expressing claudin-5 
fibers in the quadriceps muscle of the rAAV6-claudin-5 vector-injected leg also confirms that the 
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expression of the vector from the intramuscular injection was localized to the site of injection, 





Figure 9. Immunohistochemical staining of rAAV5-claudin-5 vector (1 x 1011 vg) and PBS 
treated dystrophin-deficient TA muscles at eight weeks of age. A) Claudin-5 
immunofluorescence staining showed that rAAV6-claudin-5 vector at 1 x 1011 vg injected into TA 
muscles of mdx mice transduced a majority of muscle fibers. B) Merged claudin-5 (red) and 
DAPI (blue) immunofluorescence stained-TA muscles of mdx mice at eight weeks of age 
injected with rAAV6-claudin-5 vector at 1 x 1011 vg showed that the claudin-5 expressing fibers 
in rAAV6-claudin-5-treated skeletal muscle did not exhibit a large number of fibers with central 
nuclei, a marker of damage to the skeletal muscle. C) Hematoxylin and eosin staining on TA 
muscles of mdx mice injected with rAAV6-claudin-5 vector at 1 x 1011 vg showed few regions of 
damage to the skeletal muscle. D) Claudin-5 immunofluorescence staining showed a lack of 
claudin-5 expressing muscle fibers in PBS-injected TA muscles of mdx mice, which indicated 
the proof-of-principle that the rAAV6-claudin-5 vector upregulated claudin-5 expression in 
dystrophin-deficient skeletal muscle. E) Merged claudin-5 and DAPI immunofluorescence 
stained-TA muscles of mdx mice at eight weeks of age injected with PBS showed a large 
number of fibers with central nuclei. F) Hematoxylin and eosin staining on TA muscles of mdx 
mice injected with PBS showed more regions of damage, indicated by necrosis of myocytes and 
increased fibrosis, to the skeletal muscle in PBS-injected mdx mice at eight weeks of age 
compared to rAAV6-claudin-5 vector-injected mdx mice (C). These results indicated that the 




F. rAAV6-claudin-5 transduced more dystrophin-deficient skeletal muscle 
fibers at a dose of 5 x 1011 vg.  
 
The rAAV6-claudin-5 vector was injected into the left and right TA muscles of each 
mouse at 5 x 1011 vg and 1 x 1012 vg, respectively, in  four week-old mdx mice (Group 2, n=2) in 
order to test which dose achieved the highest or complete transduction of claudin-5 in TA 
muscle fibers. The mice were dissected at eight weeks of age, and the injected TA muscles 
were harvested. Whole TA muscle composites of claudin-5 immunofluorescence staining 
(Figure 10) showed that rAAV6-claudin-5 vector at 5 x 1011 vg exhibited a high number of 
claudin-5 expressing muscle fibers. Quantitation of central nuclei via claudin-5 and DAPI 
immunofluorescence staining showed that this dose also maintained the highest number of 
claudin-5 expressing muscle fibers without central nuclei. These results indicated that 
administration of rAAV6-claudin-5 vector to dystrophin-deficient skeletal muscle at a dose of 5 x 
1011 vg transduced the highest amount of muscle fibers in which claudin-5 expression prevented 





Figure 10. Claudin-5 immunofluorescence staining of TA muscles of mdx mice at eight weeks 
of age injected with rAAV6-claudin-5 vector at 1 x 1011 vg, 5 x 1011 vg, and 1 x 1012 vg, 
respectively. Mdx mice injected with rAAV6-claudin-5 vector at 5 x 1011 vg exhibited the highest 
number of claudin-5 (red) expressing skeletal muscle fibers without central nuclei.  
(Bar equals 1mm) 
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G. Increased claudin-5 expression via rAAV6-claudin-5 (5 x 1011 vg) 
prevented cumulative degeneration and regeneration cycles and 
maintained skeletal muscle integrity in dystrophin-deficient skeletal 
muscle.  
 
Upon confirming that the rAAV6-claudin-5 vector at 5 x 1011 vg transduced the highest 
amount skeletal muscle fibers without central nuclei, the vector was administered at this dose to 
additional four week-old mdx mice (Group 3). These mice were dissected at eight weeks of age, 
and the injected TA muscles were harvested. Whole composites of claudin-5 (red) and DAPI 
(blue) immunofluorescence stains (virus-injected: Figure 11A and PBS-injected: Figure 11C) on 
TA muscles of mdx mice injected with rAAV6-claudin-5 vector at 5 x 1011 vg showed that the 
rAAV6-claudin-5 vector transduced approximately 70% of dystrophin-deficient skeletal muscle 
fibers, and further that only 22% of claudin-5 expressing skeletal muscle fibers contained 
cumulative regeneration and degeneration cycles indicative of fiber damage, compared to 48% 
in PBS-injected mdx mice at eight weeks of age. The overall lack of central nuclei in claudin-5 
expressing fibers in rAAV6-claudin-5 vector-injected TA dystrophin-deficient muscles compared 
to PBS-injected TA muscles was shown to be statistically significant (p=0.00663) using a one-
way ANOVA, supporting the hypothesis that claudin-5 ectopic expression helps compensate for 
dystrophin-deficiency in skeletal muscle. Whole composites of anti-mouse IgG 
immunofluorescence stains (virus-injected: Figure 11B and PBS-injected: Figure 11D) on TA 
muscles of mdx mice treated with rAAV6-claudin-5 vector at 5 x 1011 vg and PBS indicated a 
lack of major muscle membrane damage in skeletal muscle at eight weeks of age. These results 
indicated that claudin-5 expression maintained skeletal muscle integrity and prevented damage 









Figure 11. Immunofluorescence staining of TA muscles of mdx mice of rAAV6-claudin-5 vector 
at 5 x 1011 vg and PBS injected treatment groups. A) Composite of claudin-5 (red) and DAPI 
(blue) immunofluorescence staining of TA muscles of mdx mice injected with rAAV6-claudin-5 
vector at 5 x 1011 vg showed that this dose transduced approximately 70% of muscle fibers and 
further demonstrated that only 22% of claudin-5 expressing skeletal muscle fibers contained 
central nuclei. C) Composite of claudin-5 and DAPI immunofluorescence staining of TA muscles 
of mdx mice injected with PBS demonstrated that 48% of muscle fibers contained central nuclei 
at eight weeks of age. C) Composite of anti-mouse IgG immunofluorescence staining of TA 
muscles of mdx mice injected with rAAV6-claudin-5 vector at 5 x 1011 vg indicated a lack of 
major muscle membrane damage at eight weeks of age. D) Composite of IgG 
immunofluorescence staining of TA muscles of mdx mice injected with PBS also indicated a 
lack of major muscle membrane damage at eight weeks of age. One way-ANOVA revealed that 
TA muscles of mdx mice injected with rAAV6-claudin-5 vector at 5 x 1011 vg exhibited 
significantly less central nuclei than PBS-injected TA muscles of mdx mice, which indicated that 
the virus prevent muscle membrane damage in dystrophin-deficient skeletal muscle at eight 





Discussion for Aim 1: To determine whether claudin-5 reduction in 
cardiomyocytes is sufficient to cause cardiomyopathy.  
 
This experiment identifies initial signs of compromised cardiac function indicative of 
the onset of a cardiomyopathic phenotype and simultaneous reductions in the claudin-5 
protein in a claudin-5 knockdown mouse model. While claudin-5 reduction in the 
myocardium has not yet caused significantly reduced ejection fractions or definitive 
histological hallmarks of cardiomyopathy in the experimental mice compared to the 
controls, early indications of a cardiomyopathic phenotype have been identified by 
reduced ejection fractions of experimental het cre+ mice at 23 weeks post-tamoxifen 
treatment. An additional study to gather longitudinal echocardiogram data is currently 
being conducted in order to determine the timepoint at which het cre+ mice exhibit a 
significant reduction in ejection fraction as a result of loss of claudin-5. This data and its 
future implications support the hypothesis that claudin-5 may be necessary to maintain 
normal heart function and the integrity of the myocardium.  
The slow development of compromised cardiac function in het cre+ mice treated with 
tamoxifen chow presented in this study mimics the gradual development of 
cardiomyopathy in humans, confirming that mice treated with tamoxifen chow to induce 
claudin-5 reduction is more representative of the proper timepoints observed in the 
development and progression of DCM. A previous study of tamoxifen-injected mice 
showed reduced ejection fractions of het cre+ and wt cre+ mice. This indicated that 
tamoxifen injections resulted in a cre-dependent toxicity, which compromised whole 
heart function as apparent with the reduced ejection fractions of the cre+ groups. To 
alleviate the toxicity evident with tamoxifen injections, this study treated mice with 
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tamoxifen chow, administered at a lower dose per day and over a longer period of time. 
Echocardiograms of 14 week-old mice treated with tamoxifen chow showed that het 
cre+ mice had lower ejection fractions than any other genotype of tamoxifen-chow 
treated mice, yet it was higher than tamoxifen-injected mice of the same age, indicating 
the elimination of the cre-dependent toxicity. The observation that tamoxifen chow-
treated het cre+ mice develop a cardiomyopathic phenotype at a slower rate than 
tamoxifen-injected mice, combined with PCR analysis comparing the two groups, further 
confirmed that tamoxifen chow administration was a viable treatment because it avoided 
the toxic effects apparent with tamoxifen injections.  
The strengths of this paper lie in its attempt to determine causation between claudin-
5 reductions and the development of DCM in a novel mouse model. While many 
laboratories study heart failure, few are investigating the claudin-5 protein and its role in 
the progression of DCM and heart failure. This study identified a cre-dependent toxicity 
issue with tamoxifen injections and concluded that tamoxifen chow administration is a 
viable and effective alternative to knockdown claudin-5 expression in the myocardium, 
which is congruent with results from other publications.1 This finding has further 
implications in other mouse models that utilize tamoxifen to activate the cre-lox system 
to prevent protein expression. This paper also provides promise of a cardiomyopathic 
phenotype through longitudinal echocardiograms of the experimental mice.  
Despite the progression of initial signs of cardiomyopathy in tamoxifen chow-treated 
mice at 20, 25, and 29 weeks of age, the dobutamine stress test did not induce a 
cardiomyopathic phenotype in 25 week-old het cre+ mice. This data is limited because 
the mice underwent short-term trials, so we will continue to perform longitudinal 
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echocardiograms on the tamoxifen chow-treated mice with and without stress to 
determine if they develop significantly reduced ejection fractions as a result of claudin-5 
reductions. Future experiments consisting of additional stress tests, longitudinal data 
from aged mice, or a new mouse model will be necessary to identify if loss of claudin-5 
is sufficient to cause cardiomyopathy. Another potential limitation is that the 
echocardiogram machinery may not be sensitive enough to detect differences in cardiac 
function in CKD mice. If few differences are found in future measurements from echoes 
between the het cre+ and wt cre- mice, mice will undergo cardiac MRI on a vertical bore 
11.7 Telsa, 30-mm bore magnetic resonance imaging system. This test will examine 





Discussion for Aim 2: To determine whether claudin-5 expression helps protect 
skeletal muscle from the degenerative effects of dystrophin-deficiency.  
 
This experiment provides evidence that treatment with rAAV6-claudin-5 vector in the 
mdx model of muscular dystrophy is able to prevent histological indicators of damage to 
the skeletal muscle. By increasing the original concentration of the vector administered 
to the skeletal muscle by 5-fold, there was an improvement in the total number of fibers 
transduced in the TA muscle and an additional statistically significant decrease in the 
amount of centrally nucleated fibers in the rAAV6-claudin-5 vector-treated skeletal 
muscles as compared to the controls. These findings support our hypothesis that 
claudin-5 ectopic expression helps prevent damage to the skeletal muscle membrane. 
However, further studies that achieve complete transduction of the skeletal muscle are 
necessary in order to prove the incontrovertible success of this therapy. 
Though the histological indiactors of muscle membrane damage in skeletal muscle 
were improved in rAAV6-claudin-5-treated dystrophic skeletal muscles, there was still 
evidence of centrally nucleated fibers present after upregulated claudin-5 expression in 
the muscles. However, there is ongoing damage to the skeletal muscle from three 
weeks of age in mdx mice, and consequently the centrally nucleated fibers observed 
upon dissection at eight weeks of age could have been damaged before claudin-5 was 
ectopically expressed. Despite this possibility, the experiment in this study was 
conducted as such because it is most clinically relevant to DMD patients, who have 
ongoing damage to their skeletal muscles and are often not diagnosed until muscle 
damage appears. Further experiments that administer rAAV6-claudin-5 vector to mdx 
mice around birth and delineate the timing of administration are necessary in order to 
determine if claudin-5 ectopic expression prior to the onset of skeletal muscle 
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membrane damage is able to prevent cumulative cycles of degeneration and 
regeneration and maximize its transduction in skeletal muscle fibers.  
The strengths of this experiment lie in its attempt to establish the potential 
therapeutic value of claudin-5. By providing evidence that claudin-5 ectopic expression 
is able to prevent significant damage to the muscle membrane in dystrophin-deficient 
skeletal muscle, there is support that upregulating claudin-5 levels could be used to 
prevent damage to the myocardium, another type of striated muscle, and potentially 
improve the condition of the heart in patients suffering from DCM. Further experiments 
additionally will need to identify practical and low-cost ways to pharmacologically 
administer therapeutic levels of claudin-5 to DMD patients. 
This data is limited because the mice were analyzed only via histological indicators 
of damage. Additional histological and physiological experiments should be conducted 
to determine if claudin-5 is able to prevent additional indicators of skeletal muscle 
pathology and assess other effects of claudin-5 ectopic expression. These future 
experiments will also help identify the mechanism of action of claudin-5 in preventing 




This paper investigated whether reductions in the claudin-5 protein were 
sufficient to cause cardiomyopathy by first knocking-down cardiac claudin-5 levels in a 
mouse model and then characterizing the phenotype of this mouse model. After 
identifying a cre-dependent toxicity in tamoxifen-injected mice, tamoxifen chow was 
administered to CKD mice and proved to be an effective treatment to knockdown 
cardiac claudin-5 levels and cause initial signs of a cardiomyopathic phenotype in the 
CKD mouse model. This supports the hypothesis that cardiac claudin-5 reduction may 
cause cardiac dysfunction characteristic of the development of DCM, and further 
characterization of the phenotype of this mouse model at later timepoints may exhibit a 
clear causative relationship between loss of claudin-5 and the development of DCM. 
 This paper also studied whether upregulating claudin-5 expression was able to 
maintain the structural integrity of skeletal muscle in a dystrophin-deficient mouse 
model. The administration of rAAV6-claudin-5 vector by 5-fold, at 5 x 1011 vg, showed 
that increased claudin-5 expression significantly prevented cumulative degeneration 
and regeneration cycles and maintained skeletal muscle integrity in dystrophin-deficient 
skeletal muscle. This study helps identify claudin-5 as a potential therapeutic target for 
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